Skip to main content
. 2016 Dec 22;10(3):310–319. doi: 10.1093/ckj/sfw115

Table 3.

Demographics and disease characteristics at baseline and discontinuation for 61 patients discontinuing eculizumab in clinical trials

Discontinuation with subsequent TMA event Discontinuation without subsequent TMA event All discontinued patients
(n = 12) (n = 49) (n = 61)
Age at parent study baseline (years), median (range) 19.5 (0.0–80.0) 27.0 (0.0–68.0) 26.0 (0.0–80.0)
Female, n (%) 6 (50) 30 (61) 36 (59)
Identified complement mutation or autoantibody, n (%) 7 (58) 24 (49) 31 (51)
Factor H mutation 5 (42) 9 (18) 14 (23)
Time from TMA manifestation to start of eculizumab in parent trial (months), median (range) 0.7 (0.0–19.1) 0.8 (0.0–36.6) 0.8 (0.0–36.6)
Time from diagnosis to start of eculizumab in parent trial (months), median (range) 23.5 (0.0–112.5) 1.0 (0.0–288.0) 1.4 (0.0–288.0)
Duration of eculizumab treatment before discontinuation (weeks), median (range) 19 (1–116) 48 (1–231) 27 (1–231)
Time to TMA manifestation after discontinuation (weeks), median (min–max) 13 (4–127)
Follow-up time after discontinuation (weeks), median (min, max) 14 (4–151) 24 (0–145) 24 (0–151)
eGFR (mL/min/1.73 m2), median (range)
At parent study baseline 22.8 (10.0–105.5) 15.7 (5.3–102.0) 19.1 (5.3–105.5)
At discontinuation 36.5 (10.1–151.3) 42.9 (6.6–126.7) 41.5 (6.6–151.3)
Dialysis, n (%)
 At parent study baseline 4 (33) 20 (41) 24 (39)
 At discontinuation 0 (0) 12 (25) 12 (20)
Kidney transplant before start of parent study, n (%) 3 (25) 13 (27) 16 (26)

eGFR, estimated glomerular filtration rate; TMA, thrombotic microangiopathy.